News & insights
EMA
Articles from Apotek Analytics.
-

GLP-1 Drugs may risk investments in other essential treatments
Diabetes care in poorer settings drew attention from two directions.
-

Lilly’s retatrutide beats Ozempic. Artiva drops its autoimmune cell therapy after two trial deaths
Eli Lilly’s ‘triple-G’ drug retatrutide beat Novo Nordisk’s Ozempic on blood sugar and weight loss in a head-to-head phase 3 trial in type 2 diabetes, though with more side effects and treatment discontinuations.
-

Pfizer, Roche and AstraZeneca lead a week of drug discovery deals
Pfizer, Roche and AstraZeneca each struck discovery deals reported at $500m or more, as regulators in the UK, US and Europe signalled changes in how they weigh evidence.